http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2204000-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_634715a790f7ef0163a61e9f364bebcd |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S435-822 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S435-849 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S435-873 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P17-182 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P17-185 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-19 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P41-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P17-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4427 |
| filingDate | 1995-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce85af753a34609b652026eb4bc79f6f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9dac313aa16555b3b4fd64854d23d358 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_966429c2c7a34bd1882ff56aa03ad95a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1b9b0f16f8d47ca1cf955dc2a80ce53 |
| publicationDate | 1996-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2204000-A1 |
| titleOfInvention | Enantioselective preparation of pharmaceutically active sulfoxides by bioreduction |
| abstract | A compound of formula (II), either as a single enantiomer or in an enantiomerically enriched form, wherein Het1 is (a) or (b), and Het2 is (c) or (d), and is (e) or (f) (wherein N in the benzimidazole moiety of Het2 means that one of the carbon atoms substituted by any one of R6 to R9 optionally may be exchanged for an unsubstituted nitrogen atom; R1, R2 and R3 are the same or different and selected from hydrogen, alkyl, alkoxy optionally substituted by fluorine, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenylalkyl, phenylalkoxy; R4 and R4' are the same or different and selected from hydrogen, alkyl, aralkyl; R5 is hydrogen, halogen, trifluoromethyl, alkyl, alkoxy; R6-R9 are the same or different and selected from hydrogen, alkyl, alkoxy, halogen, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, trifluoroalkyl or adjacent groups R6-R9 may complete together with the carbon atoms to which they are attached optionally substituted ring structures; R10 is hydrogen or alkoxycarbonyloxymethyl; R11 is hydrogen or forms an alkylene chain together with R3; R12 and R13 are the same or different and selected from hydrogen, halogen or alkyl) is obtained by stereoselective bioreduction of a compound of formula (II) in racemic form. |
| priorityDate | 1994-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 59.